Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelgeneBUE:CELG 10 EV-to-EBITDA is 12.63 as of Sep. 14, 2026, which is 54% below its 10-year median of 27.70. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Celgene's enterprise value is ARS4,605,377.62 Mil.
Celgene's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 was ARS364,639.50 Mil. Therefore, Celgene's EV-to-EBITDA for today is 12.63.
The historical rank and industry rank for Celgene's EV-to-EBITDA or its related term are showing as below:
BUE:CELG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 25 Med: 27.7 Max: 35.2
Current: 1.1
During the past 13 years, the highest EV-to-EBITDA of Celgene was 35.20. The lowest was 25.00. And the median was 27.70.
BUE:CELG's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 13.23
vs BUE:CELG: 1.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Celgene's share price for today is ARS0.00.
Celgene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Celgene's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Celgene's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Celgene's EV-to-EBITDA falls into.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS364,639.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene (BUE:CELG) has a EV-to-EBITDA of 12.63 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Celgene. This is 54% below median its historical median of 27.70. Over the past decade, Celgene's EV-to-EBITDA has ranged from 25.00 to 35.20.
Is Celgene's EV-to-EBITDA too high?
Celgene's current EV-to-EBITDA of 12.63 is 54% below median its 10-year median of 27.70. Over the past 10 years, this metric has ranged from a low of 25.00 to a high of 35.20. The Drug Manufacturers industry median EV-to-EBITDA is 13.23. Celgene's value of 12.63 is 4.5% below this industry median. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's EV-to-EBITDA compare to GILD and BIIB?
Celgene's EV-to-EBITDA of 12.63 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBITDA is 13.23. Celgene's value of 12.63 is 4.5% below this benchmark. Historically, Celgene's own EV-to-EBITDA has ranged from 25.00 to 35.20 over the past decade. While the company's 10-year median is 27.70 vs. the industry median of 13.23, Celgene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.23, based on 728 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celgene's current EV-to-EBITDA of 12.63 is 4.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Celgene. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current EV-to-EBITDA is 12.63, which is 54% below median its own 10-year median of 27.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current EV-to-EBITDA of 12.63. The current EV-to-EBITDA is 12.63, which is 54% below median its 10-year median of 27.70 and 4.5% below the Drug Manufacturers industry median of 13.23. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Celgene (BUE:CELG), the current EV-to-EBITDA is 12.63 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 
